Volasertib - Boehringer Ingelheim

Drug Profile

Volasertib - Boehringer Ingelheim

Alternative Names: BI-6727

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Class Amides; Antineoplastics; Piperazines; Pteridines; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer
  • No development reported Chronic myelomonocytic leukaemia; Solid tumours; Urogenital cancer

Most Recent Events

  • 20 Dec 2017 Boehringer Ingelheim, Yale University, Massey Cancer Center and Sidney Kimmel Comprehensive Cancer Center withdraws a phase I trial prior to enrolment for T-cell lymphoma and B-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (NCT02875002)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(First-line therapy, In adolescents, In children) in Austria (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(First-line therapy, In adolescents, In children) in Belgium (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top